Key facts
- Crossbow Therapeutics’s last known valuation is $125.0M (Jul 2023).
- It has raised $198.3M across 2 recorded rounds; the latest was Early Stage VC ($30.3M) in Sep 2025.
- Notable investors include Mirae Asset Capital, Arkin Capital, Pfizer Ventures, Eli Lilly and Company Foundation, MPM BioImpact — 13 tracked in total.
- Crossbow Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently Sep 2025 ($30.3M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Crossbow Therapeutics
Funding rounds
2 roundsAbout Crossbow Therapeutics
Developer of a biotechnology company intended to enhance the quality of life for individuals suffering from cancer. The company's therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets, an efficient and selective approach to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer, enabling patients to improve their lives by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 41
- Website
- crossbowtx.com/
- Ownership
- Privately Held (backing)
Crossbow Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Crossbow Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Crossbow Therapeutics in its N-PORT filings yet. We sweep new filings monthly.